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ABSTRACT
Incretin-based agents, called gliptins or dipeptidyl 
peptidase-4 inhibitors (DPP-4), are currently considered 
a promising therapeutic option. It has been known 
for a long time that these drugs effectively improve 
glycaemic control, which is reflected by significant 
HbA1c reduction, without increasing the rate of hypo-
glycaemia or body weight gain, and that they do not 
have significant adverse effects. Is it, however, enough 
to consider them as ‘safe’? No, certainly not. Currently, 
when assessing the safety of glucose-lowering drugs, 
the effect on cardiovascular system must be also (and 
first of all) taking into account. Except for glucose-
-lowering activity, gliptins have multiple pleiotropic 
effects and, additionally, are safe in terms of cardiovas-
cular risk, which was proved based on the results from 
large clinical trials such as SAVOR-TIMI, EXAMINE and, 
the most recent, TECOS. The future will show whether 
long-term follow-up of patients treated with gliptins 
and the results of further trials will confirm current 
knowledge about DPP-4 inhibitors and expectations 
associated with this class of drugs. (Clin Diabet 2015; 
4, 6: 238–242)
Key words: DPP-4, cardiovascular safety, type 2 
diabetes
Introduction
Despite progress in diagnostics and treatment, 
vascular complications of diabetes remain the most 
important problem of contemporary diabetology and 
significantly deteriorate the patients’ quality of life. 
They contribute to increased diabetes-related morbid-
ity and mortality, and, as a consequence, to reduced 
life expectancy compared with general population. It 
seems that chronic hyperglycaemia remains a key factor 
leading to development and subsequent progression of 
vascular complications, besides broad-sense environ-
mental factors and a genetic predisposition. Despite 
treatment intensification, most patients with diabetes 
have poor metabolic control. Therefore, although there 
are many oral antidiabetic drugs and insulin prepara-
tions available nowadays, new therapies mimicking 
physiological mechanism are still searched for [1–4]. 
The observation that food ingestion or enteral 
glucose administration leads to significantly stronger 
stimulation of insulin secretion by pancreatic b-cells 
compared with intravenous glucose administration 
raised an interest in glucagon-like peptide-1 (GLP-1). 
This phenomenon is called incretin effect.
The incretin effect plays a key role in the regula-
tion of glucose metabolism in healthy subjects and is 
responsible for about 50–70% of postprandial insulin 
response. This effect is mediated by several active 
peptides released by intestinal cells. Among these 
peptides, glucagon-like peptide-1 (GLP-1) and glucose-
-dependent insulinotropic peptide (GIP) play the most 
important role in the meal-induced insulin secretion. 
In healthy subjects, the release of GLP-1 in response to 
food ingestion occurs very quickly (within less than 10 
minutes) and is correlated with insulin secretion into 
the portal circulation. In patients with type 2 diabetes 
or impaired glucose tolerance (IGT), this response is 
abnormal, which leads to reduced postprandial insulin 
secretion [5–8].
The treatment of diabetes must be individually 
tailored for each and every patient, both in terms of 
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therapeutic target and its achievability. Various mecha-
nisms leading to disease development should be taken 
into account. The treatment demands continuous and 
close cooperation with the patient and has to be multi-
directional and consistent with current therapeutic 
guidelines. When adjusting individual treatment regi-
men, patient’s quality of life should also be considered. 
Efforts to achieve blood glucose normalization as safely 
as possible is of key impotance in prevention and slowing 
down the progression of chronic complications of diabe-
tes. On the other hand, the impact of intensive glicaemic 
control on macrovascular complication is disputable. 
Large clinical trials, ACCORD (Action to Control Cardio-
vascular Risk in Diabetes), ADVANCE (Action in Diabetes 
and Vascular Disease-Preterax and Diamicron Modified 
Release Controlled Evaluation) and VADT (Veterans Af-
fairs Diabetes Trial), that were designed and performed 
to prove beneficial effect of intensive treatment on re-
duction of cardiovascular events in patients with type 2 
diabetes, failed to show any reduction in macrovascular 
complications in the intensive antidiabetic treatment 
arm. Only in the ADVANCE study a trend was observed 
towards the reduction in cardiovascular mortality by 12% 
in the intensive treatment group. Moreover, the results 
of the ACCORD study revealed increased mortality in 
patients who underwent intensive treatment. The rea-
son for this observation still remains unclear; however, 
the results of above-mentioned trials gave an impulse 
to change guidelines for the management of type 2 
diabetes. It was concluded that the treatment should 
be far more individualized. For every patient, the risk 
for hypoglycaemia, the level of diabetes education and 
the cost-benefits relationship of specific therapy should 
be considered [9–13]. 
Type 2 diabetes is one of major cardiovascular risk 
factors. Epidemiology data indicate that cardiovascular 
complications are responsible for about 65% of deaths 
in type 2 diabetes patients. Additionally, over 60% of 
patients diagnosed with stable or unstable coronary 
artery disease (CAD) have glucose metabolism distur-
bances, such as impaired fasting glucose (IFG), IGT or 
overt type 2 diabetes.
Diabetes has been diagnosed in 20–45% of clinical 
trial participants, including patients hospitalized for 
acute coronary syndrome (ACS), who had no history 
of diabetes. In this group of patients, diabetes is more 
prevalent in women than in men (41.6 vs. 30.7%). Many 
years ago, Haffner et al. published results from clinical 
trials that suggested that diabetes should be regarded 
as a coronary heart disease (CHD) equivalent [10]. The 
increase in cardiovascular risk in diabetic patients is 
caused not only by diabetes per se, but also by the 
presence of other cardiovascular risk factors [14–16].
Therefore, establishing the principles for long-term, 
safe, well-tolerated and effective therapy in patients with 
diabetes (mainly cardiovascular) complications of various 
severity, is a significant issue related to new classes of 
drugs, such as incretin-based agents. New antidiabetic 
drugs should not only influence glycaemic control, but 
also contribute to decrease in cardiovascular morbidity 
and mortality in patients with type 2 diabetes. Taking the 
above into account, in December 2008 Science Board 
of the Food and Drug Administration (FDA) issued a 
guidance requiring the assessment of cardiovascular risk 
for all new molecules used for the treatment of type 2 
diabetes. This guidance specifies methodology of clinical 
trials and registration of cardiovascular events defined 
as mortality due to cardiovascular diseases, non-fatal 
myocardial infarction and/or ischaemic stroke as well as 
hospitalization due to acute coronary syndrome and the 
need for coronary revascularization. It is recommended 
that these trials should be performed in diabetic patients 
with increased cardiovascular risk, in patients aged > 65 
years, and in patient with kidney dysfunction, assuming 
the follow-up period of ≥ 2 years [17]. 
These trials are designed to show that the use 
of antidiabetic drugs as one of the standard option 
for the treatment of diabetes is not associated with 
the increase in cardiovascular risk (cardiovascular 
safety) compared with placebo. However, it should 
be highlighted that they are not designed to show 
cardiovascular benefits resulting from HbA1c reduc-
tion. Cardiovascular safety and cardiovascular benefits 
should be assessed regardless of the HbA1c reduction.
DPP-4 inhibitors, also known as gliptins, are a 
group of oral glucose-lowering drugs whose mecha-
nism of action is based on competitive inhibition of 
dipeptidyl peptidase-4 activity, and subsequent increase 
in incretin hormone concentration, mainly GLP-1 and 
GIP. These hormones stimulate insulin secretion by 
b-cells and decrease glucagon concentration in glucose-
-dependent fashion. They improve glycaemic control, 
both in fasting state and after meals. Available data 
from clinical studies indicate possible regeneration 
of pancreatic b-cells. There are four DPP-4 inhibitors 
available in Poland: sitagliptin (Januvia, Merck Sharp 
& Dohme), vildagliptin (Galvus, Novartis), saxagliptin 
(Onglyza, Bristol Myers Squibb/AstraZeneca) and lina-
gliptin (Trajenta, Boehringer Ingelheim).
Given that GLP-1 receptors’ expression was found 
not only in pancreatic islets, but also in the heart, vas-
cular endothelium, gastrointestinal tract, central (hypo-
thalamus) and peripheral nervous systems, lungs and 
kidneys, DPP-4 inhibitors as a class of antidiabetic drugs 
offer unique benefits for type 2 diabetes patients that 
extent beyond the impact on glycaemic control [18, 19].
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Effect on body weight
Obesity is one of the main risk factors for devel-
opment and progression of type 2 diabetes, but also 
cardiovascular diseases per se. Many of the drugs 
currently used for the treatment of type 2 diabetes, 
induce weight gain (sulphonylureas, thiazolidinediones, 
insulin). Incretin-based agents are weight-neutral or 
promote weight reduction [5–7, 19–22].]
Antiatherogenic effect
DPP-4 inhibitors have beneficial effect on inde-
pendent cardiovascular risk factors. Besides glucose 
level fluctuations, in patients with diabetes these factors 
include postprandial lipid levels, hypertension, obesity, 
insulin resistance and compensatory hyperinsulinaemia. 
All these factors increase oxidative stress and epithelial 
dysfunction, exert prothrombotic and proinflammatory 
effect, activate parasympathetic system and, as a result, 
stimulate atherogenesis. DPP-4 inhibitors have favourable 
effect on lipid profile by reducing the serum concentra-
tion of total cholesterol, LDL cholesterol, triglycerides 
and postprandial lipoproteins reach in triglycerides and 
increasing the serum concentration of HDL cholesterol. 
These drug promote the reduction of hs-CRP concentra-
tion, decrease plasminogen activator inhibitor-1 (PAI-1) 
and B-type natriuretic peptide (BNP) activities and increase 
adiponectin concentration. This effect is independent 
from body weight reduction [21, 23–25].
Hypotensive effect
Native GLP-1 exerts diuretic action and increases 
sodium excretion in response to volume overload and 
the increase in serum sodium concentration, and there-
fore it can, to some degree, reduce blood pressure. 
DPP-4 therapy also results in slightly decreased blood 
pressure. In published clinical trials, systolic blood pres-
sure reduction ranged from 2 to 5 mm Hg (p < 0.05), 
while no influence on diastolic blood pressure was 
shown [21, 23–25]. 
Cardioprotective effect
Cardioprotective action through incretin effect has 
been shown not only for native GLP-1, but also for GLP-1 
(9–36) peptide, a product of GLP-1 (7–36) degradation 
by DPP-4. It has been found that administration of 
GLP-1 (9–36) during myocardial reperfusion improved 
myocardial function in GLP-1 receptor knock-out ani-
mal model, providing a significant protection against 
ischaemic/reperfusion damage, and induced vessel dila-
tion by mechanism associated with nitric oxide/cGMP 
pathway that does not require active GLP-1 receptor. 
In a study assessing the influence of DPP-4 inhibi-
tors on a global function of left ventricle in patients with 
myocardial ischaemia, it has been found that admin-
istration of the drug resulted in a significant improve-
ment in global and regional left ventricular function. 
Furthermore, myocardial regeneration due to stem cell 
mobilization was observed in patients after myocardial 
infarction who were administered DPP-4 inhibitor and 
granulocyte-colony stimulating factor (G-CSF). Moreo-
ver, it has been shown that DPP-4 inhibition promotes 
blood vessel dilation and peripheral resistance decrease 
due to the degradation of some vasoactive peptides, 
such as neuropeptide Y or neuropeptide P [21, 23–26]. 
Effect on cardiovascular risk
In 2012, a systemic review was published that 
included a meta-analysis of 18 randomized clinical tri-
als comprising 8,500 type 2 diabetes patients (among 
them almost 5,000 patients treated with DPP-4 inhibi-
tor), with a meanfollow-up period of 46 weeks. It was 
shown that these drugs have beneficial impact on 
cardiovascular risk in this special population. Relative 
risk for adverse cardiovascular events (cardiovascular 
mortality, non-fatal myocardial infarction, acute coro-
nary syndrome, stroke, arrhythmia and heart failure) 
was significantly lower in patients receiving DPP-4 in-
hibitor (RR 0.48; 95% Cl 0.1–0.75, p = 0.001) compared 
with the groups receiving other therapies. Relative risk 
for non-fatal myocardial infarction or acute coronary 
syndrome was 0.4 and was significantly decreased 
compared with other therapies (95% Cl 0.18–0.88; 
p = 0.02). The authors are however cautious in draw-
ing final conclusions. They suggest that the observed 
difference was not necessarily related to the risk reduc-
tion by DPP-4 inhibitors, but may have resulted from 
the impact of other comparators on this risk increase 
(sulphonylureas, thiazolidinediones or metformin) [27].
Therefore, the final answer for the question: 
‘Whether and to what extent does the therapy with 
DPP-4 inhibitors influence cardiovascular outcomes?’ 
will depend on the results of the trials designed ac-
cording to FDA recommendation, aiming to objectively 
assess the impact of long-term treatment with this 
class of drugs on pre-defined cardiovascular endpoints. 
In 2013, the results of the first of these trials, 
SAVOR-TIMI 53 (The Saxagliptin Assessment of Vascular 
Outcomes Recorded in Patients with Diabetes Melli-
tus–Thrombolysis in Myocardial Infarction), were pub-
lished. This multicentre, randomized, double-blind trial 
including 16,492 patients evaluated the efficacy and 
safety of saxagliptin alone or in combination with other 
glucose-lowering drugs, including insulin, in type 2 
diabetes patients aged > 40 years, with HbA1c > 6.5%, 
who had concomitant cardiovascular disease or at least 
2 cardiovascular risk factors. The meanfollow-up period 
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was 2.1 years. This study showed that saxagliptin added 
to standard glucose-lowering medication in patients at 
increased cardiovascular risk did not contribute to re-
duction or increase of the risk of the composite primary 
endpoint defined as cardiovascular death, myocardial 
infarction or ischaemic stroke. Thus, the study demon-
strated non-inferiority of saxagliptin versus placebo. 
However higher rate of hospitalization for heart failure 
was observed in the saxagliptin group (3.5% vs. 2.8%; 
RR 1.27; 95% CI, 1.07–1.51; p = 0.007). It should be 
however noted that the patients with the highest risk 
for hospitalization were previously diagnosed with 
heart failure, increased concentration of natriuretic 
peptide or chronic kidney disease. 
The rate of hypoglycaemia-related hospitalization 
was similar in both groups; however, in the saxagliptin 
group significantly more patients reported at least one 
episode of hypoglycaemia [1,264 patients (15.3%) vs. 
1,104 patients (13.4%); p < 0.001]. Severe hypoglycae-
mic episodes were noted in 177 patients (2.1%) treated 
with saxagliptin compared with 140 patients (1.7%) in 
the placebo group (p = 0.047) [28].
Alogliptin was another DPP-4 inhibitor for which 
the data were published from the cardiovascular safety 
trial meeting FDA requirements. Multicentre, rando-
mized, placebo-controlled, double-blind EXAMINE 
(Alogliptin after Acute Coronary Syndrome in Patients 
with Type 2 Diabetes) trial included 5,380 patients with 
type 2 diabetes and recent acute coronary syndrome 
(myocardial infarction or angina pectoris) that oc-
curred within 15–90 days prior to enrolment. The mean 
follow-up period was 1.5 years. The primary endpoint, 
defined as cardiovascular death, non-fatal myocardial 
infarction or non-fatal stroke, occurred with similar 
frequency in both study groups. No significant differ-
ences were shown between the groups in terms of the 
secondary endpoint, including additionally theneed for 
revascularization due to unstable angina. The rate of 
hypoglycaemic episodes was comparable between the 
group receiving active treatment and in the placebo 
group. In 2015 the results of post-hoc analysis were 
published that showed no significant differences in 
composite endpoint including cardiovascular death and 
hospitalization due to heart failure. A limitation of this 
study seems to be relatively short follow-up period [29].
The results of another study determining cardio-
vascular safety in type 2 diabetics treated with sitag-
liptin — TECOS (The Trial to Evaluate Cardiovascular 
Outcomes after Treatment with Sitagliptin) — were 
also published in 2015. This was, similarly as SAVOR 
TIMI and EXAMINE, a randomized, double-blind and 
prospective trial. A total of 14,671 type 2 diabetes 
patients with baseline cardiovascular complications 
were followed-up. Composite primary endpoint was 
defined as cardiovascular death, non-fatal myocardial 
infarction, non-fatal stroke or hospitalization due to 
unstable angina. The meanfollow-up of 3 years was 
longer than in previous trials. No significant differences 
were found for primary endpoint between sitagliptin 
treatment and comparator, which demonstrated non-
inferiority of sitagliptin. Similarly, hospitalization rate 
due to heart failure was similar in both groups (RR 
1.00; 95% CI, 0.83–1.20; p = 0.98). Adding sitagliptin 
to previous therapy did not increase the risk for hypo-
glycaemia [30]. 
Another study, evaluating the most recently regis-
tered DPP-4 inhibitor, linagliptin, started in 2010. The 
CAROLINA (Cardiovascular Outcome Study of Linagliptin 
Versus Glimepiride in Patients With Type 2 Diabetes) 
trial is a multicentre, randomized, double-blind and 
placebo-controlled observation aiming to assess the 
efficacy and safety of linagliptin therapy in type 2 
diabetes patients aged 40–85 years, with documented 
cardiovascular disease or at least 2 cardiovascular risk 
factors. The primary and secondary endpoints are similar 
to those in TECOS, SAVOR-TIMI 53 and EXAMINE trials 
(cardiovascular death, non-fatal myocardial infarction or 
stroke, hospitalization due to unstable angina pectoris). 
The end of the study and publication of its results are 
planned for 2018. It should be, however, noted that 
among described above trials only in this one a reference 
group receives active comparator, glimepiride, rather 
than placebo. Available randomized controlled trials 
(RCT) for linagliptin including over 9000 patients with 
type 2 diabetes show clearly that there is no risk increase 
not only versus placebo but also, which is particularly 
important, versus active comparators [31]. 
Conclusions
Summing up, it should be highlighted that al-
though DPP-4 inhibitors offer unique benefits for 
patients with type 2 diabetes extending beyond the 
impact on glycaemic control, our knowledge of full 
therapeutic potential of incretin axis, including possible 
protective role on cardiovascular system, needs further 
research. Based on the analysis of available data from 
clinical trials, it may be stated that these drugs reduce 
blood pressure, increase left ventricular ejection frac-
tion, have favourable effect on lipid profile and improve 
endothelial function; however, we have to wait for the 
results of further trials with DPP-4 to receive conclusive 
answer whether long-term treatment with this class 
of antidiabetic drugs translates into real reduction of 
cardiovascular risk. 
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